# Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

> **NCT03946111** · PHASE2,PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 3 (actual)

## Conditions studied

- Binge-Eating Disorder
- Obesity

## Interventions

- **DRUG:** Naltrexone and Bupropion
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03946111
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-07
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-05
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03946111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03946111, "Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03946111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*